September 26, 2024 Webinar
This session explored cutting-edge cancer risk screening technologies and their role in longevity optimization. Early cancer detection is a critical component of maximizing healthspan and lifespan.
Topics Covered
Genetic Cancer Risk Assessment
Hereditary Cancer Syndromes
- BRCA1/BRCA2 mutations
- Lynch syndrome genes
- Li-Fraumeni syndrome
- Comprehensive panel testing options
Polygenic Risk Scores
- Multi-gene risk assessment
- Interpreting risk scores
- Actionable findings
- Limitations and considerations
Epigenetic Cancer Markers
Methylation-Based Detection
- cfDNA methylation patterns
- Multi-cancer early detection tests
- Galleri and similar technologies
- False positive considerations
Biological Age and Cancer Risk
- Epigenetic age acceleration and cancer
- GrimAge cancer predictions
- Monitoring changes over time
Liquid Biopsy Technologies
Circulating Tumor DNA (ctDNA)
- Early detection capabilities
- Monitoring applications
- Current limitations
- Future directions
Multi-Cancer Early Detection (MCED)
- Available commercial tests
- Sensitivity and specificity
- Cost-benefit analysis
- Integration with standard screening
Prevention Strategies
- Risk-reducing interventions
- Enhanced surveillance protocols
- Lifestyle modifications
- Chemoprevention options
Key Speakers
Bobby Brooke - Executive Director, Clock Foundation
- Cancer screening technology overview
- Risk assessment interpretation
- Prevention strategy discussion
Key Takeaway
Combining genetic, epigenetic, and liquid biopsy screening provides comprehensive cancer risk assessment that can guide personalized prevention and early detection strategies.
